RE:Yosprala a possible AD med --trillion plus $ market size!!An additional comment on Yosprala AD possibilities is that the FDA and many other Biotech participants have been saying that to get effective treatments for the extremely complex CNS diseases, that combinations of more than one drug will likely need researching. This is because there are a lot of variations in how the disease acts within different patients, different phases of the disease and also different brain diseases themselfs and difficulty diagnosing what disease and patients uniquenesses are..... As a result of Aspirins MOAs and anti-inlamatory characteristics, and now with the Yosprala solution to higehr dosing, I am thinking Yosprala has a reasonable chance of being used in combination treatments for AD and CNS and in a platform capacity, to most researched CNS combo treatments...